POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, followi
The trial was registered June 20, 2024, at Clinicaltrials.gov (NCT06475274 https://clinicaltrials.gov/study/NCT06475274 ). The trial including the participating EU countries is also registered with the EUCT number 2024-510658-28 under https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-510658-28-00 . The first patient was enrolled August 26, 2024.
Authors
- Antonino Ginel (ORCID: https://orcid.org/0000-0002-8820-7545)
- Alexander Zarbock (ORCID: https://orcid.org/0000-0002-2124-1714)
- C. David Mazer (ORCID: https://orcid.org/0000-0003-2566-4308)
- Benoît de Varennes (ORCID: https://orcid.org/0000-0002-2579-9774)
- Klaus Matschke
- Andrej Myjavec
- Christian Strauß
- Maxime Laflamme
- Michael Reusch
- J Böhm
- Tobias E. Larsson
- Jan Burkert
Institutions
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- Hospital de Sant Pau (ES)
- Royal Victoria Hospital (CA)
- University Hospital in Motol (CZ)
- University Hospital Münster (DE)
- Deutsches Herzzentrum der Charité (DE)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- University Hospital Hradec Králové (CZ)
- Deutsches Herzzentrum München (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- Trials
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s13063-025-09124-x
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00